Categories

Category: Jessica DaMassa

Local Doctors Get the “Centers of Excellence” Treatment: Embold Health’s CEO on Data-Driven Quality

By JESSICA DaMASSA, WTF HEALTH

Apparently, self-insured employers hot on better managing their healthcare spend are finding truth (and dollars) in Embold Health’s mantra that “quality is the best, most sustainable way to control costs.” This health tech startup is applying the old “Centers of Excellence” framework to the individual physician level; helping identify high-performing primary care docs and specialists in local markets for employers who not only want to offer their employees better quality care, but also improve the healthcare system in the communities in which they live and work.

Daniel Stein, Embold Health’s co-Founder & CEO, explains the company’s model, which is being perfected with one of the most demanding-yet-coveted “health activist” employers out there: Walmart. In this particular case, Walmart is actually incentivizing its employees to go to the providers ranked highest by Embold’s assessment, which looks at physician performance along three categories: 1) appropriateness of care; 2) outcomes; and 3) cost-effective compared to peers in-market. Backed by the robust national BlueCross BlueShield dataset, the information Embold Health is collecting, analyzing, and doling out to employers can definitely cause some health systems to take pause — and their docs to bristle. So, how does Embold Health diffuse potential blowback? Here’s where the competitive nature of local healthcare, particularly in the world of primary care, becomes clutch. Tune in to hear the details, including some very interesting stats, as well as Embold’s latest endeavors to help docs make better referrals to specialists.

#Healthin2Point00, Episode 182 | Sidecar Health, Folx, TimelyMD & more

On Episode 182 of Health in 2 Point 00, we’ve actually got deals less than $100 million. Starting off with one though, Sidecar Health raises $125 million bringing their total to $163 million. Folx raises $25 million providing telehealth for the LGBTQ+ community and growing fast, TimelyMD raises $60 million providing telehealth for colleges, another MSK company SWORD Health raises $25 million and GetWellNetwork acquires Docent Health for an undisclosed amount of money. —Matthew Holt

#Healthin2Point00, Episode 181 | SPAC-ing rumors & more deals

Today on Health in 2 Point 00, Jess asks me about Lyra Health raising $187 million — this is their third raise in less than a year — and gets my take on the SPAC rumor for 23andMe, which is valued at $2.5 billion and just raised $82.5 million in December, and the rumor about Ro following Hims & Hers in a SPAC. Sharecare IS planning on “SPAC-ing” and recently acquired Doc.ai, and DarioHealth acquires Upright Technologies for $31 million. —Matthew Holt

One-Price, 30-Day Warranty, Payment at Discharge: Carrum Health’s CEO on Changing How We Buy Surgery

By JESSICA DaMASSA, WTF HEALTH

No copays. No coinsurance. No surprise out-of-network anesthesiologist fees or pre-op imaging bills. Just one, single price (that you see in advance) tells you EXACTLY what you’ll be paying for your surgical care on Carrum Health. Backed by the recent close of a $40M Series A funding round, the health tech startup’s CEO Sach Jain talks through all the ways his company is looking to disrupt how we buy surgical care. Standardized bundle pricing is just the beginning. Carrum requires its Centers of Excellence (and each of their docs) to pass a proprietary 50-point inspection before they can join the platform, AND every surgery must be backed by a 30-day Warranty! How have they convinced providers to jump through these kinds of hoops? With a growing client-base of self-insured employers (Sach says they have several Fortune 100 and Fortune 500 clients) and payment-in-full made to providers upon discharge, the case for additional revenue and zero A/R days is pretty compelling to a health system. And what about the other side of the business model? Tune in to find out why Sach believes Carrum Health’s “marketplace” approach will appeal to the growing base of “activist” employers whose HR benefits administrators are becoming more and more adept at building-their-own healthcare networks.

Medable’s CEO: Covid19 Vaccine Will Start Big Pharma’s Era of De-Centralized Clinical Trials

By JESSICA DaMASSA, WTF HEALTH

Covid 19 vaccine development may have mainstreamed questions about how to hasten drug development timelines, but Medable, a health tech startup that offers researchers a way to de-centralize clinical trials, has been working to solve this problem for five years. Freshly funded with a $91M Series C raise, co-founder and CEO Michelle Longmire talks through the benefits of “liberating” clinical trials from academic research centers and sending them onto devices into patient’s homes. Traditionally, drug development processes average more than 10 years, cost millions of dollars, and are limited in the diversity of patients they can recruit because of the heavy focus on the geographic location of the research team conducting the trial. Medable’s digital platform breaks these limitations, reducing drug development timelines and costs by making it easier for researchers to draw study participants from anywhere. More importantly, it makes the novel medicines being tested by the trial available to a bigger, more diverse array of patients. Despite the gains made in 2020 toward the de-centralized clinical trial model (Medable’s revenue shot up 500%), there’s concern that Big Pharma may return to the business processes of old once the pandemic is under control. Does Michelle think last year make enough of an impact to change their business model for good? Find out what’s ahead for the future of pharma.

#Healthin2Point00, Episode 180 | Signify Health IPO, OneDrop-Bayer-SCOR Partnership, & more

On Health in 2 Point 00, this time we have Jess tell us about OneDrop, Bayer, and SCOR’s new partnership, creating a chronic condition-specific life insurance policy using OneDrop’s platform and SCOR’s risk predictive engine. On Episode 180, Jess asks me about Signify Health filing for IPO – a real IPO, not a SPAC one, Lumiata getting $14 million working on predictive analytics, and Neuroflow getting $20 miillion in a Series A led by Magellan. —Matthew Holt

Hims & Hers CEO on IPO, Push into Primary Care, Target & More

By JESSICA DaMASSA, WTF HEALTH

On the eve of the finalization of their SPAC IPO and New York Stock Exchange debut as $HIMS, Hims & Hers CEO, Andrew Dudum, sat down with Jess DaMassa to talk about his wellness company’s transition into full-on healthcare provider. With new primary care, mental health care, and covid19 testing services launched as a result of the pandemic, Hims & Hers has expanded beyond their initial dermatology and sexual health core to provide telehealth-plus-pharmacy services for a growing range of chronic conditions, mental health issues, and everyday health concerns commonly tackled by PCPs. How far into healthcare delivery will Hims & Hers go? What types of acquisitions or innovations will be necessary to compete with the likes of Teladoc/Livongo, Optum, or the slew of virtual-first primary care clinics currently vying to be healthcare’s “digital front door”? And, what are we to make of that fact that Hims & Hers has gone retail: appearing on the shelves of every Target store in the US? Healthcare’s changing, and we get a fired-up Andrew to wax philosophical on why companies like his — that are consumer-focused, disrupting the healthcare “experience,” AND slowly eroding the healthcare payment model with a customer base willing to pay out-of-pocket — will be leading the way to a next-generation healthcare model.

#Healthin2Point00, Episode 179 | Inauguration Day Edition

Today on Health in 2 Point 00, we’ve made it to Inauguration Day! On Episode 179, we have over $300 million in deals and a SPAC IPO. Jess asks for my take on Hims & Hers going public, primary care chatbot company K Health raising $132 million, digital pathology company Paige raising $100 million, and ACO management company Aledade getting another $100 million. —Matthew Holt

Hinge Health’s CEO on $3B Valuation, Stretch Toward 2022 IPO

By JESSICA DaMASSA, WTF HEALTH

Hinge Health kicked off 2021 with a massive $300M Series D, driving the digital health musculoskeletal care company to a $3B valuation that, normally, would have sent health tech pundits into full-on IPO rumor mode…except that Hinge Health’s co-founder & CEO Daniel Perez beat them to it! We get into the details behind those comments (from what shall now be known as “the chatty Reuters interview”) where he not only revealed the company’s IPO plans, but also talked about how Hinge is well on it’s way to hit $200M in revenue. If 2021 is a year that Dan says will be focused on getting the business “operationally mature” enough to go public, what, exactly will be on the agenda? We dive into the competitive landscape, talk market size (Dan says more than 50% of employees on employer sponsored plans already have access to Hinge Health), and explore whether or not there are designs to expand into comorbidities common to back and joint pain, like mental health, obesity, diabetes, etc. Says Dan, “We’re going to use the capital to really invest in our innovation and R&D team and to stay different. We’re not just going to do the obvious moves.” Tune in for all the details on exactly what that means and why Dan thinks it’s central to Hinge Health’s market leadership in the MSK care space.

#Healthin2Point00, Episode 178 | Talkspace IPO, Accolade buys 2ndMD & more

Today on Health in 2 Point 00, Jess admires my new COVID-safe ski gear, designed to provide the right amount of coverage to the right part of your face at the right time. On Episode 178, Jess asks me about Talkspace finally getting its SPAC IPO together with a $1.4 billion valuation – this was a long time coming. Accolade acquires 2nd.MD for $460 million, Dina Health raises $7 million in a Series A, and Komodo Health raises $44 million and acquires the consulting business from Mavens. —Matthew Holt

Registration

Forgotten Password?